Clinical Trial Update: Phase III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Fibrillation [Phase 3]

View source ↗

Summary

Phase 3 tolerance and efficacy study of RSD1235 in patients with atrial fibrillation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• RSD1235

Snippet

Sponsor: Advanz Pharma | Conditions: Atrial Fibrillation | Phase 3 | Status: COMPLETED